New schizophrenia drug shows promise in early trial
NCT ID NCT00862992
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested three different doses of MP-214 (cariprazine) in 34 adults with schizophrenia. The goal was to check safety, how the drug moves through the body, and whether it helps control symptoms. Participants took the drug once daily for 14 days, starting low and increasing to a fixed dose.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cariprazine (MP-214)
- What this could lead to
- If successful, this could lead to a new oral medication option for managing schizophrenia symptoms.
- What could go wrong
- This is a small, early-phase study with only 34 participants and short 14-day treatment. Results may not apply to all patients, and side effects are still being identified.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
34 people
The number who actually took part.
- Start date
-
Apr 2008
- Finished
-
Sep 2009
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients meeting DSM-IV-TR criteria for schizophrenia * PANSS total score \<= 120 during the observation period * Patients who have been treated with oral antipsychotics within 4 weeks before informed consent * Patients whose consent is obtained from themselves in written form Exclusion Criteria: * Patients who have defined as any mental disorder other than "Schizophrenia" based on the criteria of DSM-IV-TR * History of drug or alcohol abuse * Concurrent Parkinson's disease * History of, or concurrent spastic disorders like epilepsy, cerebrovascular disease, anuresis or adynamic(= paralytic) ileus, malignant syndrome, diabetes, hepatic disorder * Patients who exhibit abnormalities on Physical Examination, have abnormal vital signs, ECG, or clinical laboratory values * Current cataract during the observation period * History of shock or anaphylactoid symptoms to drugs The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hoyu Hospital
Kure, Hiroshima, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia